484 / 1631
Background
•
In HD11, 30Gy was superior to 20Gy
after 4 cycles of ABVD
•
In HD11, there was no difference
between 30Gy and 20Gy after 4
cycles of BEACOPP
•
Hypothesis: The addition of
brentuximab vedotin will allow for
reduction in ISRT dose to minimize
late effects of treatment
Eich et al, JCO 2010;28: 4199-4206.
4XABVD+30Gy IFRT
4XABVD+20Gy IFRT
4xBEACOPP+30Gy IFRT
4XBEACOPP+20Gy IFRT